

1 Short Communication

2  
3 ***Trypanosoma brucei*: inhibition of cathepsin L is sufficient to kill**  
4 **bloodstream forms**

5  
6 Dietmar Steverding<sup>a,\*</sup>, Stuart A. Rushworth<sup>a</sup>, Bogdan I. Florea<sup>b</sup>, Herman S.  
7 Overkleef<sup>b</sup>

8  
9 <sup>a</sup> *Bob Champion Research & Education Building, Norwich Medical School, University of*  
10 *East Anglia, Norwich, NR4 7UQ, UK*

11 <sup>b</sup> *Leiden Institute of Chemistry, Leiden University, 2333 CC Leiden, The Netherlands*  
12

13  
14 \_\_\_\_\_  
15 \* Corresponding authors.

16 Tel: +44-1603-591291; fax: +44-1603-591750.

17 *E-mail address:* dsteverding@hotmail.com (D. Steverding)  
18

## ABSTRACT

The lysosomal cysteine protease activity of *Trypanosoma brucei* comprises a cathepsin B enzyme (*TbCATB*) and a cathepsin L enzyme (*TbCATL*). Inhibition of the cysteine protease activity is lethal to bloodstream-form trypanosomes but it was not entirely clear which of the two enzymes are essential for survival of the parasites. Here we show that the vinyl sulfone compound LU-102 selectively inhibits *TbCATL* without affecting *TbCATB* and the proteasomal trypsin-like activity within trypanosomes. Therefore, the trypanocidal activity displayed by LU-102 can be attributed solely to the inhibition of *TbCATL* demonstrating that this enzyme is essential to the survival of *T. brucei*.

### *Keywords:*

*Trypanosoma brucei*

African trypanosomiasis

Cysteine protease

Protease inhibitor

Bloodstream forms of *Trypanosoma brucei* express two cathepsin-like cysteine proteases, cathepsin B (*TbCATB*) and cathepsin L (*TbCATL*) [1,2]. With respect to the three subspecies of *T. brucei*, *T. b. brucei*, *T. b. rhodesiense* and *T. b. gambiense*, the enzymes show high sequence identity to each other (*TbCATL*: >98%; *TbCATB*: >99%). The two enzymes are localised to the lysosomal compartment and are involved in the degradation of endocytosed host proteins [3,4]. *TbCATL* is responsible for the majority of the cysteine protease activity [5]. Both proteases have been implicated to be essential for the survival of the parasite [3,4]. RNA interference data indicated the essentiality of *TbCATB* despite only a modest reduction of 32% of the *TbCATB* protein [4] while chemical target validation studies using small-molecule cysteine proteases inhibitors pointed towards *TbCATL* as the vital enzyme [6]. Using the newly developed compound LU-102 (Fig. 1), we show here that inhibition of *TbCATL* alone is sufficient to kill bloodstream forms of *T. brucei* *in vitro*.

The compound LU-102 is a peptidyl vinyl sulfone and was initially developed as an inhibitor of the trypsin-like activity of the mammalian proteasome [7]. By contrast, LU-102 was recently shown not to inhibit the trypsin-like activity of the proteasome of *T. brucei* [8]. The observed trypanocidal activity of LU-102 was subsequently attributed to the activity of the compound to inhibit also cathepsins [7,8]. Other targets could be excluded because peptidyl vinyl sulfones react exclusively with active site cysteine sulfhydryl and threonine hydroxyl; they do not react with the serine hydroxyl of serine proteases [9].

First, the inhibitory selectivity of LU-102 for *TbCATB* and *TbCATL* was determined using *T. brucei* cell extracts with the fluorogenic substrates Z-RR-AMC (benzyloxycarbonyl-arginyl-arginyl-7-amido-4-methyl coumarin) and Z-FR-AMC (benzyloxycarbonyl-phenylalanyl-arginyl-7-amido-4-methyl coumarin). Whereas Z-RR-AMC is cleaved by *TbCATB* but not by *TbCATL*, both *TbCATB* and *TbCATL* hydrolyse Z-FR-AMC [10,11]. LU-102 showed a dose-dependent inhibitory effect on the Z-FR-AMC hydrolysing activity with a half-maximal inhibitory concentration (IC<sub>50</sub>) of 0.39  $\mu$ M (Fig. 2A). As hydrolysis of Z-FR-AMC is mainly due to the activity of *TbCATL*, this finding indicates that LU-102 is an inhibitor of cathepsin L. On the other hand, the Z-RR-AMC hydrolysing activity was unaffected by LU-102 (Fig. 2A). As Z-RR-AMC is only cleaved by *TbCATB*, this result suggests that LU-102 does not

inhibit this enzyme. The remaining Z-FR-AMC hydrolysing activity observed at 100  $\mu$ M LU-102 (14.4% of control) was probably due to uninhibited *TbCATB* activity and/or to *TbCATL* that was not completely inhibited.

Next, the trypanocidal activity of LU-102 was determined with bloodstream forms of *T. brucei* using the resazurin (Alamar blue) assay described previously [12]. LU-102 showed a dose-dependent effect on the growth of trypanosomes with a MIC (minimum inhibitory concentration, i.e., that concentration of a compound at which all cells were killed) value of 25  $\mu$ M and a GI<sub>50</sub> (50% growth inhibition, i.e., that concentration of a compound necessary to reduce the growth rate of cells by 50% to that of controls) value 10.2  $\mu$ M (Fig 2B). Whereas a MIC value was not determined previously, the GI<sub>50</sub> value was comparable to that recently published (6.9  $\mu$ M [8]). Based on the findings that LU-102 does not inhibit *TbCATB* (see above) and the trypsin-like activity of the trypanosomal proteasome [8], the trypanocidal activity of the compound seems to be solely due to inhibition of *TbCATL*, indicating that blocking the activity of *TbCATL* is sufficient to kill bloodstream forms of *T. brucei*.

In order to prove that the trypanocidal activity of LU-102 is indeed only due to inhibition of *TbCATL*, bloodstream forms of *T. brucei* were incubated with the compound for 2 h at the lethal concentration of 25  $\mu$ M (MIC value; see Fig. 2B) and the residual peptidase activity in cell extracts was measured using Z-FR-AMC and Z-RR-AMC. The Z-FR-AMC hydrolysing activity was inhibited by 95.0% after incubating trypanosomes for 2 h with 25  $\mu$ M LU-102 (Fig. 3A). The remaining hydrolytic activity of 5.0% was most likely due to *TbCATB* as the Z-FR-AMC hydrolysing activity was almost completely abolished (by 99.6%) in parasites incubated with 25  $\mu$ M of the non-selective cysteine protease inhibitor Z-Phe-Ala-diazomethylketone (Z-FA-DMK) for 2 h (Fig. 3B). On the other hand, the Z-RR-AMC hydrolysing activity was only inhibited by 27.0% after exposing the parasites for 2 h to 25  $\mu$ M LU-102 (Fig. 3A). However, Z-RR-AMC hydrolysing activity in trypanosomes treated with LU-102 was not statistically significantly different from that of control parasites (Fig. 3A). In contrast, treatment of trypanosomes with 25  $\mu$ M Z-FA-DMK for 2 h resulted in 94.6% inhibition of the Z-RR-AMC hydrolysing activity (Fig. 3B). These findings confirm the suggestion that LU-102 is not a potent inhibitor of *TbCATB*. In addition, an inhibition of

*TbCATB* by 27.0% would certainly not be sufficient to kill bloodstream forms of *T. brucei*. For example, the CATB-specific inhibitor CA-074 was shown to inhibit *TbCATB* in trypanosomes by 95% after incubating the parasites with 100  $\mu$ M of the compound for 2 h, yet CA-074 displayed no trypanocidal activity [6].

There was a slight difference in the inhibitory potency of LU-102 when using cell extract and live trypanosomes. Whereas 100  $\mu$ M LU-102 inhibited the Z-FR-AMC hydrolysing activity by 85.6% in cell extract, 25  $\mu$ M of the compound caused 95.0% inhibition of this peptidolytic activity in live trypanosomes (compare Fig 2A with Fig. 3A). Likewise, 100  $\mu$ M LU-102 blocked the Z-RR-AMC hydrolysing activity by only 4.2% in cell extract, whereas 25  $\mu$ M of the compound inhibited this peptidolytic activity by 27.0% in live trypanosomes (compare Fig 2A with Fig. 3B). However, it has been shown that many cysteine protease inhibitors suppress more efficiently *TbCATL* and *TbCATB* activity within trypanosomes than in trypanosome cell lysates [6]. The reason for this is that the intralysosomal milieu is a reducing environment [13-15] which facilitates the inactivation reaction of cysteine protease inhibitors with the active site cysteine residue. This suggestion was confirmed by demonstrating that cathepsin enzymes are more efficiently inhibited by cysteine protease inhibitors in the presence of thiols (dithiothreitol (DTT) and glutathione) [5,6]. To determine whether a reducing environment enhances the inhibitory potency of LU-102, the effect of the reducing agent DTT on the inhibition of the Z-FR-AMC and Z-RR-AMC hydrolysing activity by LU-102 in cell extracts was investigated. In the absence of DTT, pre-incubation of cell extracts with 25  $\mu$ M of LU-102 inhibited the hydrolysis of Z-FR-AMC by 69.9% (Fig 3C). In contrast, in the presence of 2.5 mM DTT, pre-treatment of cell extracts with 25  $\mu$ M LU-102 lead to 94.8% inhibition (Fig. 3C), which was almost identical to the extent of inhibition observed in live trypanosomes (95.0%; see Fig. 3A). Likewise, pre-treatment of cell extract with the compound in the absence of DTT resulted in the inhibition of the Z-RR-AMC hydrolytic activity by just 7.4% while in the presence of the thiol the hydrolysis of the peptide was inhibited by 21.7% (Fig. 3D). The inhibition in presence of DTT was similar to that observed for LU-102 in live trypanosomes (27.0%; see Fig. 3B). However, as for live trypanosomes, the inhibition of the Z-RR-AMC hydrolysing activity by LU-102 in cell extracts

in the presence of DTT was not statistically significantly different from that of the DMSO control (Fig. 3B). These findings confirm that the inhibition reaction of LU-102 with the active site cysteine residue of *TbCATB* and *TbCATL* is enhanced in a reducing environment.

Previously it was shown that inhibition of lysosomal cysteine proteases in bloodstream-form trypanosomes is associated with the accumulation of transferrin in the lysosome [16,17]. Further analysis revealed that only blockage of *TbCATL* resulted in considerable accumulation of transferrin in the lysosome while inhibition of *TbCATB* did not interfere with the degradation of the iron-transport protein [6]. To determine whether treatment of trypanosomes with LU-102 leads to accumulation of transferrin within the lysosome, parasites were incubated with fluorescein-labelled transferrin in the presence of 25  $\mu$ M LU-102 or Z-FA-DMK for 2 h. Treatment of trypanosomes with 25  $\mu$ M LU-102 led to the accumulation of transferrin (Fig. 3E). Based on the median of the fluorescence intensity signal, LU-102 treated trypanosomes accumulated 4.7-times more transferrin than control cells treated with DMSO alone (Fig. 3E). However, trypanosomes incubated with 25  $\mu$ M Z-FA-DMK accumulated about twice more transferrin than LU-102 treated cells (Fig. 3E). This result showed that inhibition of *TbCATL* by LU-102 also led to substantial accumulation of transferrin, a prerequisite for any CATL inhibitor in order to be trypanocidal.

Although we have recently shown that LU-102 at 10  $\mu$ M did not significantly inhibit the trypsin-like activity of the trypanosomal proteasome in cell extracts [8], there might be the possibility that at the higher concentration of 25  $\mu$ M the compound inhibits the proteasomal trypsin-like activity more readily facilitated by the intracellular reducing environment. To exclude this possibility, bloodstream forms of *T. brucei* were incubated with 25  $\mu$ M LU-102 for 2 h and the proteasomal trypsin-like activity in cell extracts was subsequently measured using the fluorogenic trypsin-like peptide substrate Boc-LSTR-AMC. Under the experimental conditions, LU-102 inhibited the trypsin-like activity by 13.5% (Fig. 3F). However, the trypsin-like activity in trypanosomes treated with LU-102 was not statistically significantly different from that of control parasites (Fig. 3F). The observed extent of inhibition of the trypsin-like activity by LU-102 within trypanosomes is in line with that recently reported in trypanosome cell extracts (13.5% inhibition at 25  $\mu$ M within cells compared to 8.7% inhibition at 10  $\mu$ M in

cell lysate) [8]. The finding shows that LU-102 also does not substantially inhibit the trypsin-like activity within trypanosomes. In addition, the observed limited inhibition of the proteasomal trypsin-like activity is certainly not sufficient to explain the trypanocidal activity of LU-102.

A previous chemical validation study using a variety of cysteine protease inhibitors provided evidence suggesting that *TbCATL* rather than *TbCATB* is essential to the survival of *T. brucei* bloodstream forms [6]. This conclusion was reached based on the observation that the CATB-specific inhibitor CA-074 displayed no trypanocidal activity although the compound inhibited almost completely the activity of *TbCATB* within trypanosomes [6]. As all other inhibitors employed suppressed considerably the activity of both *TbCATL* and *TbCATB*, it remained unclear whether not both proteases needed to be inhibited in order to kill the parasite. In this study, we have now shown that inhibition of *TbCATL* alone is sufficient to kill bloodstream forms of *T. brucei*. This was only possible as the vinyl sulfone compound LU-102 selectively inhibited the activity of *TbCATL* in trypanosomes without affecting *TbCATB* and the trypsin-like activity of the trypanosomal proteasome. The finding that *TbCATL* is essential to the survival of bloodstream forms of *T. brucei* suggests that future drug development programmes should focus on the rational design of *TbCATL* inhibitors.

## References

- [1] C.R. Caffrey, D. Steverding, D. Kinetoplastid papain-like cysteine peptidases. *Mol. Biochem. Parasitol.* 167 (2009) 12-19.
- [2] C.R. Caffrey, A.-P. Lima, D. Steverding. Cysteine peptidases of kinetoplastid parasites. *Adv. Exp. Med. Biol.* 712 (2011) 84-99.
- [3] S. Scory, C.R. Caffrey, Y.-D. Stierhof, A. Ruppel, D. Steverding, D. *Trypanosoma brucei*: killing of bloodstream forms *in vitro* and *in vivo* by the cysteine proteinase inhibitor Z-Phe-Ala-CHN<sub>2</sub>. *Exp. Parasitol.* 91 (1999) 327-333.
- [4] Z.B. Mackey, T.C. O'Brien, D.C. Greenbaum, R.B. Blank, J.H. McKerrow. 2004 A cathepsin B-like protease is required for host protein degradation in *Trypanosoma brucei*. *J. Biol. Chem.* 279 (2004) 48426-48433.

- 181 [5] D. Steverding. The cathepsin B-selective inhibitors CA-074 and CA-074Me inactivate  
182 cathepsin L under reducing conditions. *Open Enzym. Inhib. J.* 4 (2011) 11-16.
- 183 [6] D. Steverding, D.W. Sexton, X. Wang, S.S. Gehrke, G.K. Wagner, C.R. Caffrey.  
184 *Trypanosoma brucei*: chemical evidence that cathepsin L is essential for survival and a  
185 relevant drug target. *Int. J. Parasitol.* 42 (2012) 481-488.
- 186 [7] P.P. Geurink, W.A. van der Linden, A.C. Mirabella, N. Gallastegui, G. de Bruin, A.E.M.  
187 Blom, M.J. Voges, E.D. Mock, B.I. Florea, B.I., G.A. van der Marel, C. Driessen, M. van  
188 der Stelt, M. Groll, H.S. Overkleeft, A.F. Kisselev. Incorporation of non-natural amino  
189 acids improves cell permeability and potency of specific inhibitors of proteasome  
190 trypsin-like sites, *J. Med. Chem.* 56 (2013) 1262-1275.
- 191 [8] D. Steverding, B.I. Florea, H.S. Overkleeft. *Trypanosoma brucei*:  $\beta$ 2-selective  
192 proteasome inhibitors do not block the proteasomal trypsin-like activity but are  
193 trypanocidal. *Mol. Biochem. Parasitol.* 227 (2019) 1-4.
- 194 [9] J.T. Palmer, D. Rasnick, J.L. Klaus, D. Brömme. Vinyl sulfones as mechanism-based  
195 cysteine protease inhibitors. *J. Med. Chem.* 38 (1995) 3193-3196.
- 196 [10] C.R. Caffrey, E. Hansell, K.D. Lucas, L.S. Brinen, A. Alvarez Hernandez, J. Cheng, S.L,  
197 Gwaltney 2nd, W.R. Roush, Y.-D. Stierhof, M. Bogyo, D. Steverding, J.H. McKerrow.  
198 Active site mapping, biochemical properties and subcellular localization of rhodesain,  
199 the major cysteine protease of *Trypanosoma brucei rhodesiense*. *Mol. Biochem.*  
200 *Parasitol.* 118 (2001) 61-73.
- 201 [11] T.C. O'Brien, Z.B. Mackey, R.D. Fetter, Y. Choe, A.J. O'Donoghue, M. Zhou, C.S.  
202 Craik, C.R. Caffrey, J.H. McKerrow, A parasite cysteine protease is key to host  
203 degradation and iron acquisition. *J. Biol. Chem.* 283 (2008) 28934-28943.
- 204 [12] K. Merschjohann, R. Sporer, D. Steverding, M. Wink. *In vitro* effect of alkaloids on  
205 bloodstream forms of *Trypanosoma brucei* and *T. congolense*. *Planta Med.* 67 (2001)  
206 623-627.
- 207 [13] J. Isaacs, F. Binkley. Glutathione dependent control of protein disulfide-sulphydryl  
208 content by subcellular fractions of hepatic tissue. *Biochim. Biophys. Acta* 497 (1977)  
209 192-204.



- 210 [14] F. Mbemba, A. Houbin, M. Raes, J. Remacle. Subcellular localization and modification  
211 with ageing of glutathione, glutathione peroxidase and glutathione reductase activities in  
212 human fibroblasts. *Biochim. Biophys. Acta* 838 (1985) 211-220.
- 213 [15] R.L. Pisoni, T.L. Acker, K.M. Lisowski, R.M. Lemons, J.G. Thoene. A cysteine-specific  
214 lysosomal transport system provides a major route for the delivery of thiol to human  
215 fibroblast lysosomes: possible role in supporting lysosomal proteolysis. *J. Cell Biol.* 110  
216 (1990) 327-335.
- 217 [16] D.J. Grab, C.W. Wells, M.K. Shaw, P. Webster, D.C.W. Russo. Endocytosed transferrin  
218 in African trypanosomes is delivered to lysosomes and may not be recycled. *Eur. J. Cell*  
219 *Biol.* 59 (1992) 398-404.
- 220 [17] D. Steverding, Y.-D. Stierhof, H. Fuchs, R. Tauber, P. Overath. Transferrin-binding  
221 protein complex is the receptor for transferrin uptake in *Trypanosoma brucei*. *J. Cell*  
222 *Biol.* 131 (1995) 1173-1182.
- 223

## Figure legends

**Fig. 1.** Chemical structure of LU-102. The PubChem Compound Identifier (CID) of LU-102 is 71562351.

**Fig. 2.** (A) Effect of LU-102 on cysteine protease activity in cell extracts of *T. brucei*. Bloodstream forms of *T. brucei* 427-221a were harvested, washed once with PBS/1% glucose and lysed in 100 mM citrate, pH 5.0, 2% CHAPS on ice for 10 min. After centrifugation at 16873g for 5 min, aliquots of clarified cell extracts were treated with different concentrations of LU-102 (10-fold serial dilutions from 100  $\mu$ M to 1 nM) in the presence of 10% DMSO for 30 min at room temperature. Controls were treated with 10% DMSO alone. Then, 16  $\mu$ l of samples containing  $1 \times 10^6$  and  $1 \times 10^7$  cell equivalents for determining *Tb*CATB/L and *Tb*CATB activity, respectively, were added to 1984  $\mu$ l measuring buffer (100 mM citrate, pH 5.0, 2 mM DTT) containing 5  $\mu$ M Z-FR-AMC and Z-RR-AMC, respectively. After 30 min (*Tb*CATB/L) or 120 min (*Tb*CATB), the fluorescence of released AMC was measured at excitation and emission wavelengths of 360 nm and 460 nm in a BIORAD VersaFluor fluorometer. Open circles, *Tb*CATB/L activity; open squares, *Tb*CATB activity. Data are mean values  $\pm$  SD of three experiments. (B) Trypanocidal activity of LU-102. Bloodstream forms of *T. brucei* 427-221a were seeded in 96-well plates in a final volume of 200  $\mu$ l Baltz medium containing 2-fold serial dilutions of LU-102 (100  $\mu$ M to 0.78125  $\mu$ M) and 1% DMSO. Control cultures contained medium and 1% DMSO. The initial cell density was  $1 \times 10^4$  trypanosomes/ml. After 24 h incubation at 37  $^{\circ}$ C in a humidified atmosphere containing 5% CO<sub>2</sub>, 20  $\mu$ l of a 0.5 mM resazurin solution prepared in sterile PBS was added and the cells were incubated for a further 48 h so that the total incubation time was 72 h. Thereafter, the plates were read on a microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 nm. Data are mean values  $\pm$  SD of three experiments.


**Fig. 3.** (A,B) Effect of LU-102 on Z-FR-AMC and Z-RR-AMC the hydrolysis activity within trypanosomes. Bloodstream forms of *T. brucei* 427-221a ( $2 \times 10^7$ /ml) were incubated with 25

253  $\mu\text{M}$  of LU-102 or 25  $\mu\text{M}$  Z-FA-DMK in Baltz medium in the presence of 2.5% DMSO at 37  
 254  $^{\circ}\text{C}$  in a humidified atmosphere containing 5%  $\text{CO}_2$ . Control cultures were incubated in medium  
 255 containing 2.5% DMSO. After 2 h incubation, cells were harvested by centrifugation and  
 256 washed three times with PBS/1% glucose. Then, cell pellets ( $2 \times 10^7/100 \mu\text{l}$ ) were lysed in 100  
 257 mM citrate, pH 5.0, 2% CHAPS on ice for 10 min. Subsequently, lysates were centrifuged and  
 258 clarified supernatants were used to determine *TbCATB/L* and *TbCATB* activity in measuring  
 259 buffer (100 mM citrate, pH 5.0, 2 mM DTT) in the presence of 5  $\mu\text{M}$  Z-FR-AMC and Z-RR-  
 260 AMC, respectively. For *TbCATB/L* activity (A), 10  $\mu\text{l}$  of cell lysate corresponding to  $2 \times 10^6$   
 261 cell equivalents were added to 1990  $\mu\text{l}$  measuring buffer. For *TbCATB* activity (B), 60  $\mu\text{l}$   
 262 corresponding to  $1.2 \times 10^7$  cell equivalents were added to 1940  $\mu\text{l}$  measuring buffer. After 15  
 263 min (*TbCATB/L*) and 60 min (*TbCATB*) incubation at room temperature, respectively, the  
 264 release of free AMC was measured at excitation and emission wavelengths of 360 and 460 nm,  
 265 respectively, in a BIORAD VersaFluor fluorometer. Specific activities (pmol AMC  
 266 released/min/cell) were calculated using a standard curve constructed with uncoupled AMC.  
 267 Data are mean values  $\pm$  SD of three experiments. (C,D) Effect of DTT on inhibition of cysteine  
 268 peptidase activity in cell extracts of trypanosomes by LU-102. Cell extracts of bloodstream  
 269 form *T. brucei* 427-221a (prepared as described in Fig. 2) were pre-treated with 25  $\mu\text{M}$  LU-  
 270 102 or the equivalent amount of DMSO (10%) alone in the absence or presence of 2.5 mM  
 271 DTT for 30 min at room temperature. Then, 16  $\mu\text{l}$  of samples containing  $0.35\text{-}0.40 \times 10^6$  and  
 272  $0.26\text{-}0.44 \times 10^7$  cell equivalents for determining *TbCATB/L* and *TbCATB* activity,  
 273 respectively, were added to 1984  $\mu\text{l}$  measuring buffer (see Fig. 2) containing 5  $\mu\text{M}$  Z-FR-AMC  
 274 and Z-RR-AMC, respectively. After 30 min (*TbCATB/L*, C) or 120 min (*TbCATB*, D), the  
 275 fluorescence of released AMC was measured and specific activities calculated as described  
 276 above. Data are mean values  $\pm$  SD of three experiments. (E) Effect of LU-102 on the  
 277 accumulation of fluorescein-labelled transferrin in trypanosomes. Bloodstream forms of *T.*  
 278 *brucei* ( $1 \times 10^7/\text{ml}$ ) were incubated with 50  $\mu\text{g}/\text{ml}$  fluorescein-labelled bovine transferrin in  
 279 Baltz medium supplemented with 2% BSA in the presence of 25  $\mu\text{M}$  LU-102 and 2.5% DMSO  
 280 (orange line). Control cultures were treated with 2.5% DMSO alone (red line; negative control)  
 281 or with 25  $\mu\text{M}$  Z-FA-DMK plus 2.5% DMSO (blue line; positive control). After 2 h incubation,

282 cells were washed twice with PBS/1% glucose and fixed with 2% formaldehyde/0.05%  
283 glutaraldehyde in PBS. Accumulated fluorescein-labelled transferrin within trypanosomes was  
284 determined using a CyFlow® Cube 6 flow cytometer. (F) Effect of LU-102 on the proteasomal  
285 trypsin-like activity within trypanosomes. Bloodstream forms of *T. brucei* 427-221a ( $2 \times$   
286  $10^7$ /ml) were incubated with 25  $\mu$ M of LU-102 in Baltz medium in the presence of 2.5% DMSO  
287 at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>. Control cultures were incubated in  
288 medium containing 2.5% DMSO. After 2 h incubation, cells were harvested by centrifugation  
289 and washed three times with PBS/1% glucose. Then, cell pellets ( $1 \times 10^7$ /100  $\mu$ l) were lysed in  
290 10 mM Tris, 0.1 mM EDTA, pH 7.0, 0.2% NP-40, 2 mM ATP and 1 mM DTT on ice for 10  
291 min. Subsequently, lysates were centrifuged (16873g for 5 min) and clarified supernatants were  
292 used to determine the proteasomal trypsin-like activity in 50 mM HEPES, pH 7.5 with 5  $\mu$ M  
293 Boc-LSTR-AMC. After 30 min, the fluorescence of released AMC was measured and specific  
294 activities calculated as described above. Data are mean values  $\pm$  SD of three experiments.

295


296 Fig. 1



297  
298  
299

Fig. 2

**A**



**B**




Fig. 3





Fig. 3 (continued)

C



D







Fig. 3 (continued)

**E**



**F**

